2020 annual financial data
ImmunityBio 2020 Operating cash flow margin
Direct answer
Operating cash flow margin was -28,384.13%.
Operating income was -220,880,000 USD and net income was -221,851,000 USD.
Operating cash flow was -171,724,000 USD.
Get free ImmunityBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 605,000 USD
- Operating income
- -220,880,000 USD
- Net income
- -221,851,000 USD
- Operating cash flow
- -171,724,000 USD